{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T04:32:27Z","timestamp":1793248347513,"version":"4.5.0"},"reference-count":134,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jhepr.2026.102025","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T23:56:16Z","timestamp":1788566176000},"page":"102025","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoimmune hepatitis: Special groups and treatment gaps"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2511-7980","authenticated-orcid":false,"given":"Aldo J.","family":"Montano-Loza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8027-3073","authenticated-orcid":false,"given":"Joost PH.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6736-2255","authenticated-orcid":false,"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.102025_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J Hep"},{"key":"10.1016\/j.jhepr.2026.102025_bib2","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2025.03.017","article-title":"EASL Clinical Practice Guidelines on the management of autoimmune hepatitis","volume":"83","year":"2025","journal-title":"J Hep"},{"key":"10.1016\/j.jhepr.2026.102025_bib3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1136\/gutjnl-2024-333171","article-title":"British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis","volume":"74","author":"Gleeson","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.jhepr.2026.102025_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2018.17","article-title":"Autoimmune hepatitis","volume":"4","author":"Mieli-Vergani","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhepr.2026.102025_bib5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/17474124.2025.2491531","article-title":"Natural history and long-term management of autoimmune hepatitis","volume":"19","author":"Smith","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib6","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/liv.15217","volume":"42","author":"Lohse","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/cld.873","article-title":"Immunopathogenesis of autoimmune hepatitis","volume":"15","author":"Assis","year":"2020","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.102025_bib8","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1172\/JCI65414","article-title":"Medullary thymic epithelial cell depletion leads to autoimmune hepatitis","volume":"123","author":"Bonito","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhepr.2026.102025_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102619","article-title":"Regulatory T cells in autoimmune hepatitis: an updated overview","volume":"119","author":"Longhi","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhepr.2026.102025_bib10","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhepr.2019.08.001","article-title":"Liver homing of clinical grade Tregs after therapeutic infusion in patients with autoimmune hepatitis","volume":"1","author":"Oo","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/hep.31065","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American association for the study of liver diseases","volume":"72","author":"Mack","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib12","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1111\/liv.14513","article-title":"High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation","volume":"40","author":"Pape","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2217\/pgs.11.32","article-title":"A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study","volume":"12","author":"Newman","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jhepr.2026.102025_bib14","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/ueg2.70083","article-title":"Non-adherence to standard therapy in autoimmune hepatitis: impact of steroid Use and over-the-counter medications","volume":"13","author":"Wunsch","year":"2025","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2026.102025_bib15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jhepr.2019.10.005","article-title":"Efficacy of rituximab in difficult-to-manage autoimmune hepatitis: results from the international autoimmune hepatitis group","volume":"1","author":"Than","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib16","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/liv.15970","article-title":"Rituximab is a safe and effective alternative treatment for patients with autoimmune hepatitis: results from the ColHai registry","volume":"44","author":"Riveiro-Barciela","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib17","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1097\/HEP.0000000000001089","article-title":"Efficacy and safety of infliximab in patients with autoimmune hepatitis","volume":"81","author":"Efe","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib18","article-title":"Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis","volume":"2","author":"Arvaniti","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2023.06.002","article-title":"Autoimmune hepatitis: Epidemiology, Subtypes, and presentation","volume":"28","author":"Shiffman","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.102025_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00004836-200207000-00016","article-title":"Prognosis of symptomatic vs. asymptomatic autoimmune hepatitis: a study of 68 patients","volume":"35","author":"Kogan","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102025_bib21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2008.01904.x","article-title":"Features and consequences of untreated type 1 autoimmune hepatitis","volume":"29","author":"Czaja","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib22","article-title":"Approach to the patient with acute severe autoimmune hepatitis","volume":"2","author":"Rahim","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/lt.25451","article-title":"Acute severe autoimmune hepatitis: corticosteroids or liver transplantation?","volume":"25","author":"Rahim","year":"2019","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.102025_bib24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jhep.2020.12.033","article-title":"Early liver transplantation for corticosteroid non-responders with acute severe autoimmune hepatitis: the SURFASA score","volume":"74","author":"De Martin","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib25","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/jhep.2003.50266","article-title":"Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis","volume":"38","author":"Hempfling","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib26","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.cgh.2025.02.010","article-title":"Hepatic encephalopathy and MELD-Na predict treatment benefit in autoimmune hepatitis-related decompensated cirrhosis","volume":"24","author":"Arvaniti","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib27","article-title":"Recompensation in patients with autoimmune hepatitis-related decompensated cirrhosis following immunosuppressive therapy","volume":"7","author":"Chen","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib28","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2023.04.033","article-title":"Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report","volume":"79","author":"Andrade","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib29","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1002\/hep4.1959","article-title":"Setting up criteria for drug-induced autoimmune-like hepatitis through a systematic analysis of published reports","volume":"6","author":"Bjornsson","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.102025_bib30","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2024.03.021","article-title":"Treatment response and clinical event-free survival in autoimmune hepatitis: a Canadian multicentre cohort study","volume":"81","author":"Plagiannakos","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1097\/HEP.0000000000000589","article-title":"Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry","volume":"79","author":"Slooter","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib32","article-title":"Liver stiffness measurement predicts clinical outcomes in autoimmune hepatitis","volume":"6","author":"Olivas","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib33","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.cgh.2019.11.013","article-title":"Rapid response to treatment of autoimmune hepatitis associated with remission at 6 and 12 Months","volume":"18","author":"Pape","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/oxfordjournals.qjmed.a067149","article-title":"Chronic hepatitis: effect of prolonged suppressive treatment and comparison of azathioprine with prednisolone","volume":"37","author":"Mackay","year":"1968","journal-title":"Q J Med"},{"key":"10.1016\/j.jhepr.2026.102025_bib35","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102025_bib36","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2010.06.046","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102025_bib37","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/HEP.0000000000000018","article-title":"Budesonide as first-line treatment in patients with autoimmune hepatitis seems inferior to standard predniso(lo)ne administration","volume":"77","author":"Diaz-Gonzalez","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib38","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/HEP.0000000000000940","article-title":"Optimizing thiopurine therapy in autoimmune hepatitis: a multicenter study on monitoring metabolite profiles and co-therapy with allopurinol","volume":"80","author":"Weltzsch","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib39","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100172","article-title":"Mycophenolate mofetil as second line treatment in autoimmune hepatitis - a retrospective single center analysis","volume":"5","author":"Kolev","year":"2022","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jhepr.2026.102025_bib41","article-title":"Long-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis","volume":"4","author":"Dalekos","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib42","article-title":"First results from a propensity matching trial of mycophenolate mofetil vs. Azathioprine in treatment-naive AIH patients","volume":"12","author":"Dalekos","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jhepr.2026.102025_bib43","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/MEG.0000000000001367","article-title":"Comparison of mycophenolate mofetil with standard treatment for autoimmune hepatitis: a meta-analysis","volume":"31","author":"Yu","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.jhep.2023.11.032","article-title":"An open-label randomised-controlled trial of azathioprine vs. mycophenolate mofetil for the induction of remission in treatment-naive autoimmune hepatitis","volume":"80","author":"Snijders","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib45","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jhep.2014.10.018","article-title":"Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis","volume":"62","author":"Hartl","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib46","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/liv.14280","article-title":"Permanent immunosuppression in SLA\/LP-positive autoimmune hepatitis is required although overall response and survival are similar","volume":"40","author":"Zachou","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1478-3231.2007.01444.x","article-title":"Consequences of treatment withdrawal in type 1 autoimmune hepatitis","volume":"27","author":"Montano-Loza","year":"2007","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib48","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib49","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib50","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib51","article-title":"External validation of the IAIHG autoimmune hepatitis response criteria in a multicentric real-world cohort","volume":"6","author":"Grossar","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib52","article-title":"Features and outcome of AIH patients without elevation of IgG","volume":"2","author":"Hartl","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib53","article-title":"Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis","volume":"3","author":"Laschtowitz","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib54","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1016\/j.cgh.2021.05.024","article-title":"Aminotransferases during treatment predict long-term survival in patients with autoimmune hepatitis type 1: a Landmark analysis","volume":"20","author":"Biewenga","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib55","article-title":"Isolated IgG elevation in patients with persistently normal transaminases does not affect the outcome of autoimmune hepatitis","volume":"7","author":"Diaz-Gonzalez","year":"2025","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib56","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1016\/j.jhep.2025.06.017","article-title":"The role of liver biopsy in diagnosing patients with autoimmune hepatitis - it can be acceptable to skip","volume":"83","author":"Bjornsson","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib57","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cgh.2010.07.016","article-title":"Patients with typical laboratory features of autoimmune hepatitis rarely need a liver biopsy for diagnosis","volume":"9","author":"Bjornsson","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib58","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/ajg.2015.139","article-title":"Long-term Prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis","volume":"110","author":"Dhaliwal","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102025_bib59","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70642","article-title":"Relapse after treatment withdrawal in autoimmune hepatitis: biopsy-Guided Vs. Clinically guided strategies-A meta-analysis","volume":"46","author":"Dong","year":"2026","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib60","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference Network on Hepatological diseases and the international autoimmune hepatitis group","volume":"73","author":"Lohse","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jhep.2012.09.009","article-title":"Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission","volume":"58","author":"van Gerven","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib62","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/HEP.0000000000000961","article-title":"Real-world evidence for factors associated with maintenance treatment practices among US adults with autoimmune hepatitis","volume":"81","author":"Bittermann","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib63","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jhepr.2026.102025_bib64","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.11205","article-title":"Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study","volume":"49","author":"Ravelli","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jhepr.2026.102025_bib65","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib66","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1002\/art.34672","article-title":"Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jhepr.2026.102025_bib67","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib68","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000066","article-title":"Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort","volume":"2","author":"Al Sawah","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.jhepr.2026.102025_bib69","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhepr.2026.102025_bib70","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O","article-title":"Damage in systemic lupus erythematosus and its association with corticosteroids","volume":"43","author":"Zonana-Nacach","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jhepr.2026.102025_bib71","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/apt.15528","article-title":"Adverse events related to low dose corticosteroids in autoimmune hepatitis","volume":"50","author":"van den Brand","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.102025_bib72","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1365-2133.2004.06323.x","article-title":"Guidelines for prescribing azathioprine in dermatology","volume":"151","author":"Anstey","year":"2004","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib73","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.cgh.2024.08.006","article-title":"Thiopurines and the risk of cancer in patients with inflammatory bowel disease and reference individuals without inflammatory bowel disease: a Danish nationwide cohort study (1996-2018)","volume":"23","author":"Wewer","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/jdv.12041","article-title":"Increased incidence of squamous cell carcinoma of the skin after long-term treatment with azathioprine in patients with auto-immune inflammatory rheumatic diseases","volume":"28","author":"van den Reek","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jhepr.2026.102025_bib75","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1007\/s12094-024-03839-0","article-title":"Azathioprine and risk of non-melanoma skin cancers in organ transplant recipients: a systematic review and update meta-analysis","volume":"27","author":"Kreuz","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.jhepr.2026.102025_bib76","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","article-title":"Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Chakravarty","year":"2024","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib77","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/MCG.0b013e3181a8754d","article-title":"Mycophenolate mofetil-induced colitis in children","volume":"43","author":"Phatak","year":"2009","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102025_bib78","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1097\/HEP.0000000000001271","article-title":"Health-related quality of life is impaired in people with autoimmune hepatitis: results of a multicentre cross-sectional study within the European Reference Network","volume":"82","author":"Snijders","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib79","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jhep.2013.10.035","article-title":"Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis","volume":"60","author":"Schramm","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib80","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archpsyc.62.12.1377","article-title":"Hostile marital interactions, proinflammatory cytokine production, and wound healing","volume":"62","author":"Kiecolt-Glaser","year":"2005","journal-title":"Arch Gen Psychiat"},{"key":"10.1016\/j.jhepr.2026.102025_bib81","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s11481-006-9036-0","article-title":"Stress-induced immune dysregulation: Implications for wound healing, infectious disease and cancer","volume":"1","author":"Godbout","year":"2006","journal-title":"J Neuroimmune Pharm"},{"key":"10.1016\/j.jhepr.2026.102025_bib82","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1478-3231.2010.02333.x","article-title":"Psychological stress is associated with relapse in type 1 autoimmune hepatitis","volume":"30","author":"Srivastava","year":"2010","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib83","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.jhep.2012.07.032","article-title":"Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors","volume":"57","author":"Sockalingam","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib84","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1002\/hep.30031","article-title":"The impact of autoimmune hepatitis and its treatment on health utility","volume":"68","author":"Wong","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib85","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.14309\/ajg.0000000000003857","article-title":"The risk of psychiatric disorders in patients with autoimmune hepatitis: a nationwide registry-based follow-up study","volume":"121","author":"Gronbaek","year":"2026","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102025_bib86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jcp.2005.036020","article-title":"Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C","volume":"60","author":"Skripenova","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.jhepr.2026.102025_bib87","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/liv.14900","article-title":"Autoimmune hepatitis in patients aged 70 years or older: disease characteristics, treatment response and outcome","volume":"41","author":"Dalekos","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib88","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.3748\/wjg.v25.i22.2809","article-title":"Autoimmune hepatitis treatment in the elderly: a systematic review","volume":"25","author":"Durazzo","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102025_bib89","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20-year experience","volume":"25","author":"Gregorio","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib90","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1542\/peds.2015-0578","article-title":"Incidence and characteristics of autoimmune hepatitis","volume":"136","author":"Jimenez-Rivera","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhepr.2026.102025_bib91","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2023.01.013","article-title":"Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood","volume":"78","author":"Maggiore","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib92","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1097\/MPG.0000000000002892","article-title":"Presentation and outcomes of autoimmune hepatitis type 1 and type 2 in children: a single-center study","volume":"72","author":"Roepe","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhepr.2026.102025_bib93","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/MPG.0000000000001801","article-title":"Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN Hepatology Committee position statement","volume":"66","author":"Mieli-Vergani","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhepr.2026.102025_bib94","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.jpeds.2013.05.042","article-title":"Budesonide vs. prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents","volume":"163","author":"Woynarowski","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.jhepr.2026.102025_bib95","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s10620-018-5011-x","article-title":"Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis","volume":"63","author":"Efe","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2026.102025_bib96","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2013.05.046","article-title":"Infliximab as rescue therapy in paediatric autoimmune hepatitis","volume":"59","author":"Rajanayagam","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib97","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MPG.0000000000001759","article-title":"Anti-TNFalpha treatment in children and adolescents with combined inflammatory bowel disease and autoimmune liver disease","volume":"66","author":"Nedelkopoulou","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhepr.2026.102025_bib98","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1542\/peds.2011-1900","article-title":"Successful treatment of refractory autoimmune hepatitis with rituximab","volume":"132","author":"D'Agostino","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.jhepr.2026.102025_bib99","article-title":"Treatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease","volume":"5","author":"Zachou","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib100","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1097\/HEP.0000000000001089","article-title":"Efficacy and safety of infliximab in patients with autoimmune hepatitis","volume":"81","author":"Efe","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib101","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hep.32132","article-title":"Outcomes of pregnancy in autoimmune hepatitis: a population-based study","volume":"75","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib102","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1111\/apt.16924","article-title":"Systematic review with meta-analysis: outcomes of pregnancy in patients with autoimmune hepatitis","volume":"55","author":"Si","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhepr.2026.102025_bib103","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cgh.2015.09.037","article-title":"Efficacy of 6-mercaptopurine as second-line treatment for patients with autoimmune hepatitis and azathioprine intolerance","volume":"14","author":"Hubener","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib104","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/gast.1996.v110.pm8536867","article-title":"The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine","volume":"110","author":"Pratt","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhepr.2026.102025_bib105","article-title":"6-Mercaptopurine vs mycophenolate mofetil in autoimmune hepatitis and azathioprine intolerance: a multicenter study","volume":"23","author":"Horst","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib106","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/00365521.2018.1551498","article-title":"A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis","volume":"54","author":"Hanouneh","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102025_bib107","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib108","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa021744","article-title":"Chronic renal failure after transplantation of a nonrenal organ","volume":"349","author":"Ojo","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jhepr.2026.102025_bib109","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13063-023-07832-w","article-title":"Tacrolimus vs. mycophenolate for AutoImmune hepatitis patients with incompLete response on first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial","volume":"25","author":"Stoelinga","year":"2024","journal-title":"Trials"},{"key":"10.1016\/j.jhepr.2026.102025_bib110","first-page":"193","article-title":"Cyclosporine-A Vs. Prednisolone for induction of remission in auto-immune hepatitis: Interim analysis report of a randomized controlled trial","volume":"5","author":"Nasseri-Moghaddam","year":"2013","journal-title":"Middle East J Dig Dis"},{"key":"10.1016\/j.jhepr.2026.102025_bib111","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/MPG.0000000000002776","article-title":"Autoimmune hepatitis in children: prednisone plus azathioprine Vs. Cyclosporine: a randomized trial","volume":"71","author":"Cuarterolo","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.jhepr.2026.102025_bib112","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/j.1600-6143.2006.01360.x","article-title":"Cyclosporin vs. tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis","volume":"6","author":"McAlister","year":"2006","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhepr.2026.102025_bib113","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.amjmed.2014.06.016","article-title":"Use of sirolimus in the treatment of refractory autoimmune hepatitis","volume":"127","author":"Chatrath","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.jhepr.2026.102025_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2026.102827","article-title":"Safety and efficacy of everolimus as a rescue therapy in autoimmune hepatitis","volume":"50","author":"Seltsam","year":"2026","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.102025_bib115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jhep.2026.02.026","article-title":"Integrative omics and phase IIa clinical trial identify TNF as key node in autoimmune hepatitis","volume":"85","author":"Xu","year":"2026","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib116","article-title":"B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis","volume":"4","author":"Biewenga","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhepr.2026.102025_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2023.100189","article-title":"Belimumab treatment in autoimmune hepatitis and primary biliary cholangitis - a case series","volume":"6","author":"Kolev","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jhepr.2026.102025_bib118","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"Dorner","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhepr.2026.102025_bib119","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2018-214720","article-title":"Treatment of primary Sjogren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity","volume":"78","author":"Dorner","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhepr.2026.102025_bib120","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102025_bib121","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1056\/NEJMc2311867","article-title":"JAK inhibition in STAT1 gain-of-function-mediated treatment-resistant autoimmune hepatitis","volume":"390","author":"Hadzic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102025_bib122","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16173","article-title":"A case of difficult-to-treat autoimmune hepatitis successfully managed by tofacitinib","volume":"45","author":"Gokce","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.102025_bib123","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001840","article-title":"Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension","author":"Lammert","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.102025_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103113","article-title":"Hepatic safety and efficacy of immunomodulatory drugs used in patients with autoimmune hepatitis","volume":"140","author":"Terziroli Beretta-Piccoli","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jhepr.2026.102025_bib125","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.102025_bib126","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhepr.2026.102025_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jhepr.2026.102025_bib128","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2665-9913(24)00377-1","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going?","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib129","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2025.11.027","article-title":"CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement","volume":"84","author":"Keitel","year":"2026","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jhepr.2026.102025_bib130","article-title":"Salvage therapies of autoimmune hepatitis limit proinflammatory immune cells while sparing regulatory T cells","volume":"24","author":"Derben","year":"2023","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhepr.2026.102025_bib131","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2022.08.035","article-title":"Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans","volume":"78","author":"Lim","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.102025_bib132","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00281-022-00952-6","article-title":"Tolerance and autoimmunity in the liver","volume":"44","author":"Schramm","year":"2022","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.jhepr.2026.102025_bib133","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/ph6030287","article-title":"RNAi therapeutics in autoimmune disease","volume":"6","author":"Pauley","year":"2013","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jhepr.2026.102025_bib134","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.63676","article-title":"IFN-\u0393 siRNA effectively Knocked Down IFN-\u03b3 gene expression and reduced cytokine Secretion in Peripheral blood Mononuclear cells of patients with autoimmune hepatitis","volume":"18","author":"Behfarjam","year":"2018","journal-title":"Hepat Mon"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592600296X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258955592600296X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T03:58:36Z","timestamp":1793246316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258955592600296X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":134,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S258955592600296X"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102025","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autoimmune hepatitis: Special groups and treatment gaps","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.102025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"102025"}}